TACE Clinical Trials

4 recruiting

TACE Trials at a Glance

7 actively recruiting trials for tace are listed on ClinicalTrialsFinder across 6 cities. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Beijing, Guangzhou, and Hangzhou. Lead sponsors running tace studies include First Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of University of South China, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse tace trials by phase

Treatments under study

About TACE Clinical Trials

Looking for clinical trials for TACE? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new TACE trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about TACE clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Hepatocellular Carcinoma (HCC)TACETIPS+2 more
First Affiliated Hospital, Sun Yat-Sen University206 enrolled1 locationNCT07322848
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting
Phase 1Phase 2

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Hepotacellular Carcinoma
Tongji Hospital144 enrolled1 locationNCT07282184
Recruiting
Phase 3

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Radiotherapy, AdjuvantHepatocellular Carcinoma (HCC)Immune Checkpoint Inhibitor+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences286 enrolled1 locationNCT07186621
Recruiting

The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients

CirrhosisHepotacellular Carcinoma
The First Affiliated Hospital of University of South China800 enrolled1 locationNCT07147335
Recruiting
Phase 2

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Hepatocellular CarcinomaTislelizumabOxaliplatin+3 more
Zhejiang Cancer Hospital35 enrolled1 locationNCT05920863
Recruiting
Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666